Linezolid Infusion 200mg/100mL
Linezolid is indicated for the treatment of the following infections, including cases with concurrent bacteremia, when suspected or known to be caused by susceptible strains of gram-positive anaerobic or aerobic microorganisms. Combination therapy may be clinically indicated if the pathogens include gram-negative organisms. Linezolid has activity against gram-positive bacteria only. Linezolid does not have clinical activity against gram-negative pathogens. Specific therapy against gram-negative pathogens is required if suspected or known to be present (see Pharmacokinetics and Pharmacodynamics in Humans: Pharmacodynamic Properties and General Precautions).
- Nosocomial pneumonia.
- Community-acquired pneumonia.
- Skin and soft tissue infections.
- Enterococcal infections, including those caused by vancomycin-resistant Enterococcus faecium and Enterococcus faecalis.
Pharmaceutical form
Infusion
Concentration
200mg/100mL
Combination
N/A
Disclaimer: The content of this website is for pharmaceutical industry professionals interested in creating a strategic alliance with Wexford Laboratories. This page may contain information related to health, medical conditions, physical condition and its treatment. The information contained in this site is not to diagnose a health problem and is not a substitute for the advice provided by your doctor. Always consult a doctor when in doubt about a disease and its treatment. The products are subject to the applicable patent and registration laws of each country, and may not be allowed to be registered in some markets.
